- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01199705
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)
A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Aichi Pref.
-
Nagoya city, Aichi Pref., Japan, 466-8560
- Study Site
-
-
Chiba Pref.
-
Chiba city, Chiba Pref., Japan, 260-8677
- Study Site
-
-
Gifu Pref.
-
Gifu city, Gifu Pref., Japan, 501-1194
- Study Site
-
-
Hokkaido
-
Sapporo city, Hokkaido, Japan, 060-8648
- Study Site
-
-
Miyagi Pref.
-
Sendai city, Miyagi Pref., Japan, 980-8574
- Study Site
-
-
Osaka
-
Fukuoka city, Osaka, Japan, 812-8582
- Study Site
-
Moriguchi city, Osaka, Japan, 570-8507
- Study Site
-
Osaka city, Osaka, Japan, 534-0021
- Study Site
-
-
Saitama Pref.
-
Koshigaya city, Saitama Pref., Japan, 343-8555
- Study Site
-
Tokorozawa city, Saitama Pref., Japan, 359-8513
- Study Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of PID with hypo- or agammaglobulinemia requiring IgG replacement therapy
- Intravenous IgG (IVIG) therapy at regular 3- or 4-week intervals at a stable dose for at least 3 doses prior to signing of informed consent
- Written informed consent
Exclusion Criteria:
- Newly diagnosed PID, i.e., subjects who have not previously received immunoglobulin replacement therapy
- Ongoing serious bacterial infections (SBIs: pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess) at the time of screening
- Ongoing or history of concomitant malignancies of lymphoid cells such as lymphocytic leukemia, non-Hodgkin's lymphoma, and immunodeficiency with thymoma
- Allergic or other severe reactions to immunoglobulins or other blood products recorded in the past 3 months or at the time of screening
- Pregnancy or nursing mother
- A positive result at screening on any of the following viral markers: human immunodeficiency virus-1 (HIV-1), HIV-2, hepatitis C virus, or hepatitis B virus
- Participation in a study with other investigational product during this study and within 3 months prior to screening
- Subjects who donated blood (200 mL within one month or 400 mL within 3 months prior to screening), or planning to donate blood during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IgPro20
|
IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human SCIG.
Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IgG Trough Level
Time Frame: During IVIG period (IV 1, IV 2, IV 3) and during SCIG period at weeks 16, 20, and 24
|
Geometric means of trough levels measured before 3 intravenous immunoglobulin (IVIG) infusions was compared with those of trough levels measured at steady-state for 3 subcutaneous immunoglobulin (SCIG) infusions (weeks 16, 20 and 24).
The ratio of these geometric means was the primary outcome measure.
|
During IVIG period (IV 1, IV 2, IV 3) and during SCIG period at weeks 16, 20, and 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Infection Episodes (Serious and Non-serious) by Study Period
Time Frame: Up to 36 weeks
|
Number of infection episodes (serious and non-serious) presented by study period:
|
Up to 36 weeks
|
Rate of Infection Episodes (Serious and Non-serious) by Study Period, PPS Population
Time Frame: Up to 36 weeks
|
The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods:
|
Up to 36 weeks
|
Rate of Infection Episodes (Serious and Non-serious) by Study Period, FAS Population
Time Frame: Up to 36 weeks
|
The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods:
|
Up to 36 weeks
|
Number of Days Out of Work/School/Kindergarten/Day Care or Unable to Perform Normal Daily Activities Due to Infections by Study Period
Time Frame: Up to 36 weeks
|
Median number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).
|
Up to 36 weeks
|
Number of Days of Hospitalization Due to Infections by Study Period
Time Frame: Up to 36 weeks
|
Median number of days of hospitalization due to infections, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).
|
Up to 36 weeks
|
Duration of Use of Antibiotics for Infection Prophylaxis and Treatment
Time Frame: Up to 36 weeks
|
Median number of days of use of antibiotics for infection prophylaxis and/or treatment, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).
|
Up to 36 weeks
|
Rate of All Adverse Events by Relatedness and Seriousness
Time Frame: For the duration of the study, up to 36 weeks
|
The rate of adverse events (AEs) was the number of treatment-emergent AEs over the number of infusions administered.
At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
|
For the duration of the study, up to 36 weeks
|
Rate of Mild, Moderate, or Severe Local Reactions
Time Frame: For the duration of the study, up to 36 weeks
|
In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of: infusion site discomfort, infusion site erythema, infusion site haemorrhage, infusion site induration, infusion site inflammation, infusion site pain, infusion site pruritus, infusion site swelling, injection site erythema, injection site extravasation, injection site induration, injection site irritation, injection site pain, injection site pruritus, injection site swelling, and puncture site reaction. Mild AE: Symptoms are easily tolerated and there is no interference with daily activities; Moderate AE: Discomfort enough to cause some interference with daily activities; Severe AE: Incapacitating with inability to work or do usual activity. |
For the duration of the study, up to 36 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Annualized Rate of Serious Bacterial Infections (SBIs), PPS Population
Time Frame: Up to 36 weeks
|
The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods:
|
Up to 36 weeks
|
Annualized Rate of Serious Bacterial Infections (SBIs), FAS Population
Time Frame: Up to 36 weeks
|
The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods:
|
Up to 36 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yoriyuki Shiga, CSL Behring K.K.
Publications and helpful links
General Publications
- Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency. Clin Ther. 2014 Nov 1;36(11):1616-24. doi: 10.1016/j.clinthera.2014.08.007. Epub 2014 Sep 16.
- Kanegane H, Imai K, Yamada M, Takada H, Ariga T, Bexon M, Rojavin M, Hu W, Kobayashi M, Lawo JP, Nonoyama S, Hara T, Miyawaki T. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. J Clin Immunol. 2014 Feb;34(2):204-11. doi: 10.1007/s10875-013-9985-z. Epub 2014 Feb 7.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZLB06_002CR
- U1111-1116-6379 (Other Identifier: WHO Universal Trial Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Immune Deficiency
-
Caja Costarricense de Seguro SocialCompleted
-
University Hospital, CaenCompletedPrimary Immune Deficiency DisorderFrance
-
CSL LimitedCompletedPrimary Immune Deficiency (PID)Australia
-
Therapure Biopharma IncUnknownPrimary Immune Deficiency Diseases (PIDD)United States, Canada
-
OctapharmaCompleted
-
ADMA Biologics, Inc.CompletedPrimary Immune Deficiency Disorders (PIDD)United States
-
CSL BehringCompletedPrimary Immune Deficiency | Secondary Immune DeficiencyCanada
-
University Hospital, CaenCompleted
-
Instituto Grifols, S.A.CompletedPrimary Immune Deficiency DiseaseUnited States
-
Johns Hopkins All Children's HospitalRecruitingMetabolic Disease | Primary Immune Deficiency DisordersUnited States
Clinical Trials on Immune Globulin Subcutaneous (Human) (SCIG)
-
CSL BehringCompletedPrimary Immune DeficiencyUnited States
-
University Health Network, TorontoRecruiting
-
Rutgers, The State University of New JerseyRecruitingChronic Inflammatory Demyelinating Polyneuropathy | CIDP | Immunoglobulin DeficiencyUnited States
-
Rochester General HospitalTakedaRecruitingCOPD Exacerbation AcuteUnited States
-
University of South FloridaCSL BehringCompletedChronic Inflammatory Demyelinating PolyneuropathyUnited States
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)Germany, Austria, Hungary, Sweden, United Kingdom
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)Japan
-
CSL BehringCompletedPrimary Immune Deficiency DisorderJapan
-
Baxalta now part of ShireCompleted
-
CSL BehringCompleted